The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Investigating TCTP as a biomarker for immunotherapy resistance in gastric cancer
Hyung-Don Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, discusses the challenges of first-line immunotherapy for metastatic gastric cancer. While it is the standard of care, many patients either do not respond initially or develop resistance over time, and no biomarkers have been identified to represent resistance signals in gastric cancer. Dr Kim presents a study exploring the role of translationally controlled tumor protein (TCTP), recently recognised for its role in driving immunosuppressive gradient in the tumor microenvironment. Higher TCTP levels correlate with poorer outcomes in patients with gastric cancer receiving either chemotherapy or immunotherapy, highlighting TCTP as a promising biomarker for monitoring and overcoming immunotherapy resistance. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
